BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb  In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
BioCentury | May 1, 2020
Distillery Therapeutics

YAP1 activation for recovery after spinal cord injury

DISEASE CATEGORY: Neurology INDICATION: Spinal cord injury (SCI) Activating YAP1 via inhibition of MSP and STK3 could treat SCI. In the Hippo-YAP pathway that regulates cell growth and survival, MSP and STK3 signaling phosphorylate and...
BC Extra | Jun 27, 2019
Company News

With $104M series C debut, Encoded takes on expansion of gene therapies

Encoded wants to fine-tune expression of gene therapies, and expand the indications and targets for which they can be used, taking the technology beyond the limits set by payload size. Emerging from stealth with a...
BC Innovations | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BC Innovations | Apr 2, 2019
Distillery Techniques

Grafts of human pluripotent ESC-derived cardiomyocytes for myocardial injury

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Cell therapy Grafts of cardiomyocytes derived from human pluripotent ESCs could be used to treat myocardial injury. The cardiomyocytes were generated by culturing human pluripotent ESCs with laminin 521 and...
BC Innovations | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and cell culture studies suggest inhibiting USP7 or its downstream mediator YAP1 could help treat hepatocellular carcinoma (HCC). In patient samples, tumor levels of USP7 and YAP1 proteins were higher...
BC Innovations | Jan 15, 2019
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture experiments suggest inhibiting TEAD4-YAP1 binding interactions with flufenamic acid-based compounds could help treat glioblastoma. Chemical synthesis of analogs of flufenamic acid, which binds TEAD2, in vitro testing and optimization of...
BC Innovations | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Jul 18, 2018
Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday,...
BC Innovations | Nov 16, 2017
Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
Items per page:
1 - 10 of 41